Vir, WuXi collaborating on COVID-19 mAbs

Vir and WuXi Biologics announced Tuesday a collaboration to develop and manufacture mAbs to treat COVID-19. The partnership combines Vir’s mAb discovery engine with WuXi’s development and manufacturing muscle.

Working with samples from patients who had survived infection with SARS, Vir Biotechnology Inc. (NASDAQ:VIR) said it has “identified a number of monoclonal antibodies that bind to SARS-CoV-2,” the virus that causes COVID-19. Vir is conducting research to determine if the mAbs from the closely related SARS, or additional antibodies it may identify, “can be effective as treatment and/or prophylaxis against SARS-CoV-2.”...